New drug for HER 2 + breast cancer!

In June, the FDA approved a new drug, Perjeta (pertuzumab), for HER 2 + breast cancer. It's used in combination with Herceptin and chemotherapy in previously untreated, metastatic disease.  This combination  is the only regimen to have shown a significant improvement in survival compared to Herceptin plus chemotherapy alone. Perjeta works complementary to Herceptin, as the two medicines target different regions on the HER2 receptor.